Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below

It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

NCT Number	NCT07561125
Lead Sponsor	International Peace Maternity and Child Health Hospital
Conditions	Bronchopulmonary Dysplasia
Enrollment	29 participants
Start Date	2026-04-23
Primary Completion	2027-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-23